Drug Discovery, High- Throughput, High-Content Screening
Associate Adjunct Professor
Skaggs School of Pharmacy and Pharmaceutical Sciences
Dr. Siqueira-Neto’s research has focused on development and implementation of screening assays to identify active molecules and natural products against parasites causing neglected tropical diseases.
Education:
B.S. in Biological Sciences (2003) University of Campinas, SP - Brazil; Ph.D. in Molecular Genetics (2007) University of Campinas, SP - Brazil; Postdoctoral Fellow (2007-2009) Institut Pasteur Korea - South Korea.
Awards and Honors:
CAPES Doctorate International Internship Scholarship (2005); DNDi Partnership of the Year, New Delhi, India (2010).
Leadership Experience:
Team Leader and Drug Discovery Program Coordinator at Institut Pasteur Korea (2009-2012); Kinetoplastida Core Director from the Center for Discovery and Innovation in Parasitic Diseases, UCSF & UCSD (2013-present); Assistant Adjunct Professor at Skaggs School of Pharmacy and Pharmaceutical Sciences, UCSD (2014-present).
- Development of the first High-Content Screening for Leishmania and Trypanosoma cruzi
- Dossin et al. (2008) Automated nuclear analysis of Leishmania major telomeric clusters reveals changes in their organization during the parasite's life cycle. PLoS One. 3(6):e2313.
- Siqueira-Neto et al. (2010) Antileishmanial high- throughput drug screening reveals drug candidates with new scaffolds. PLoS Negl Trop Dis. 4(5):e675.
- Freitas-Junior et al. (2012) Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?International Journal for Parasitology: Drugs and Drug Resistance. 2:11–19.
- Siqueira-Neto et al. (2012) An Image-based High- Content Screening Assay for Compounds Targeting Intracellular Leishmania donovani Amastigotes in Human Macrophages. PLoS Negl Trop Dis. (6):e1671.
- Moon et al. (2014) An Image-Based Algorithm for Precise and Accurate High Throughput Assessment of Drug Activity against the Human Parasite Trypanosoma cruzi. PLoS One. 9(2):e87188.
- Calvet et al. (2014) 4-aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency. J Med Chem. 2014 Aug 7. [Epub ahead of print]
- Drug discovery for neglected tropical diseases
- High-Throughput, High-Content Screening assay development